Cerdulatinib (original) (raw)
Cerdulatinib is a small molecule SYK/JAK kinase inhibitor in development for treatment of hematological malignancies. It has lowest nM IC50 values against TYK2, JAK1, JAK2, JAK3, FMS, and SYK. It is being developed by Portola Pharmaceuticals; in September 2018 the FDA granted orphan drug status to cerdulatinib for the treatment of peripheral T-cell lymphoma (PTCL).
| Property | Value |
|---|---|
| dbo:abstract | Cerdulatinib is a small molecule SYK/JAK kinase inhibitor in development for treatment of hematological malignancies. It has lowest nM IC50 values against TYK2, JAK1, JAK2, JAK3, FMS, and SYK. It is being developed by Portola Pharmaceuticals; in September 2018 the FDA granted orphan drug status to cerdulatinib for the treatment of peripheral T-cell lymphoma (PTCL). (en) Цердулатиниб (PRT062070, PRT2070, DMVT-502) — низкомолекулярный ингибитор тирозинкиназ SYK/JAK, пероральный препарат, разрабатываемый для терапии . Цердулатиниб — мультикиназный ингибитор, обладающий наиболее высокой специфичностью к киназам TYK2, JAK1, JAK2, JAK3, FMS и SYK. (ru) |
| dbo:casNumber | 1198300-79-6 |
| dbo:fdaUniiCode | D1LXQ45S1O |
| dbo:pubchem | 44595079 |
| dbo:thumbnail | wiki-commons:Special:FilePath/Cerdulatinib.svg?width=300 |
| dbo:wikiPageID | 58891956 (xsd:integer) |
| dbo:wikiPageLength | 3400 (xsd:nonNegativeInteger) |
| dbo:wikiPageRevisionID | 1030996494 (xsd:integer) |
| dbo:wikiPageWikiLink | dbr:Entospletinib dbr:Tumors_of_the_hematopoietic_and_lymphoid_tissues dbr:Ruxolitinib dbr:Orphan_drug dbr:Small_molecule dbc:Experimental_cancer_drugs dbr:Peripheral_T-cell_lymphoma dbr:Janus_kinase dbr:Janus_kinase_1 dbr:Janus_kinase_2 dbr:Janus_kinase_3 dbr:Food_and_Drug_Administration dbr:Fostamatinib dbr:Kinase dbc:Aminopyrimidines dbc:Protein_kinase_inhibitors dbr:Syk dbr:Portola_Pharmaceuticals dbr:Tyrosine_kinase_2 dbr:IC50 dbr:Oral_route |
| dbp:c | 20 (xsd:integer) |
| dbp:casNumber | 1198300 (xsd:integer) |
| dbp:chemspiderid | 32822046 (xsd:integer) |
| dbp:drugName | Cerdulatinib (en) |
| dbp:h | 27 (xsd:integer) |
| dbp:iupacName | 4 (xsd:integer) |
| dbp:n | 7 (xsd:integer) |
| dbp:o | 3 (xsd:integer) |
| dbp:pubchem | 44595079 (xsd:integer) |
| dbp:routesOfAdministration | dbr:Oral_route |
| dbp:s | 1 (xsd:integer) |
| dbp:smiles | CCSN1CCNC2=CC=CNC3=NC=CCN (en) |
| dbp:stdinchi | 1 (xsd:integer) |
| dbp:stdinchikey | BGLPECHZZQDNCD-UHFFFAOYSA-N (en) |
| dbp:synonyms | PRT062070, PRT2070, DMVT-502 (en) |
| dbp:unii | D1LXQ45S1O (en) |
| dbp:wikiPageUsesTemplate | dbt:Infobox_drug dbt:Cascite dbt:Chemspidercite dbt:Drugbankcite dbt:Fdacite dbt:Stdinchicite |
| dcterms:subject | dbc:Experimental_cancer_drugs dbc:Aminopyrimidines dbc:Protein_kinase_inhibitors |
| rdf:type | owl:Thing dul:ChemicalObject dbo:ChemicalSubstance wikidata:Q8386 dbo:Drug |
| rdfs:comment | Cerdulatinib is a small molecule SYK/JAK kinase inhibitor in development for treatment of hematological malignancies. It has lowest nM IC50 values against TYK2, JAK1, JAK2, JAK3, FMS, and SYK. It is being developed by Portola Pharmaceuticals; in September 2018 the FDA granted orphan drug status to cerdulatinib for the treatment of peripheral T-cell lymphoma (PTCL). (en) Цердулатиниб (PRT062070, PRT2070, DMVT-502) — низкомолекулярный ингибитор тирозинкиназ SYK/JAK, пероральный препарат, разрабатываемый для терапии . Цердулатиниб — мультикиназный ингибитор, обладающий наиболее высокой специфичностью к киназам TYK2, JAK1, JAK2, JAK3, FMS и SYK. (ru) |
| rdfs:label | Cerdulatinib (en) Цердулатиниб (ru) |
| owl:sameAs | wikidata:Cerdulatinib dbpedia-ru:Cerdulatinib https://global.dbpedia.org/id/2Xz6g |
| prov:wasDerivedFrom | wikipedia-en:Cerdulatinib?oldid=1030996494&ns=0 |
| foaf:depiction | wiki-commons:Special:FilePath/Cerdulatinib.svg |
| foaf:isPrimaryTopicOf | wikipedia-en:Cerdulatinib |
| foaf:name | Cerdulatinib (en) |
| is dbo:product of | dbr:Portola_Pharmaceuticals |
| is dbo:wikiPageRedirects of | dbr:C20H27N7O3S |
| is dbo:wikiPageWikiLink of | dbr:Peripheral_T-cell_lymphoma_not_otherwise_specified dbr:C20H27N7O3S dbr:Janus_kinase_inhibitor dbr:Portola_Pharmaceuticals dbr:Tyrosine-protein_kinase_SYK |
| is dbp:products of | dbr:Portola_Pharmaceuticals |
| is foaf:primaryTopic of | wikipedia-en:Cerdulatinib |
